Y-mAbs Therapeutics, Inc. Intellectual Property Contracts & Agreements

8 Contracts & Agreements
Browse by Subcategory
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Amendment No.1 to License Agreement dated December 17, 2020, entered into and effective on December 9, 2024, by and between the Registrant and SciClone Pharmaceuticals...
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
2025
Amendment No.3 to License Agreement dated August 20, 2015, entered into and effective on November 8, 2024, by and between the Registrant and Memorial Sloan-Kettering Cancer Center
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
2025
License Agreement dated September 11, 2024, by and between the Registrant and Princeton 202 Associates Limited Partnership
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
2024
License Agreement, entered into on October 29, 2024 and effective October 23, 2024, by and between Y-mAbs Therapeutics, Inc. and Nobelpharma Co., Ltd
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
2024
Amendment No. 2, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
2022
Amendment No. 1, dated March 18, 2021 to License Agreement, dated as of August 20, 2015 between Registrant and Memorial Sloan Kettering Cancer Center
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
2021
License Agreement dated December 17, 2020 between Y-mabs Therapeutics, Inc., and SciClone Pharmaceuticals International Ltd
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
NY
2020
License Agreement, effective as of April 15, 2020, by and among the Company, Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology
License Agreements
Y-mAbs Therapeutics, Inc.
Biotechnology
NY
2020